{"schema":"biotech.company-dossier.v1","preview":true,"service":"public-developer-preview","generatedAt":"2026-10-29T20:48:23.495Z","query":{"companies":"VRTX","category":null,"limit":20,"offset":0,"catalystOffset":0},"page":{"limit":20,"offset":0,"total":1,"returned":1,"nextOffset":null},"unmatched":[],"companies":[{"ticker":"VRTX","name":"Vertex Pharmaceuticals Incorporated","categories":["large-biotech","rare-disease"],"inCuratedUniverse":true,"sec":{"cik":null,"conformedName":null,"filingsUrl":null},"catalysts":[{"id":"7a2b4f49833a25cd","type":"approval","title":"FDA approval of Casgevy: first CRISPR therapy","drug":"Casgevy (exa-cel)","indication":"Sickle cell disease","phase":null,"date":"2023-12-08","datePrecision":"day","dateStart":"2023-12-08","dateEnd":"2023-12-08","nctId":null,"outcome":null,"confidence":null,"summary":"The FDA approved Vertex’s Casgevy (exa-cel) for Sickle cell disease on Dec 8, 2023. The company can now sell it in that market.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":null,"sourceClass":null,"verified":true,"verifiedAt":null},{"id":"73203f1445e3b17a","type":"readout","title":"VX-548 Phase 3 topline in acute pain","drug":"Journavx (suzetrigine)","indication":"Acute pain","phase":"Phase 3","date":"2024-01-30","datePrecision":"day","dateStart":"2024-01-30","dateEnd":"2024-01-30","nctId":null,"outcome":null,"confidence":null,"summary":"Vertex reported results from its Phase 3 study of Journavx (suzetrigine) for Acute pain on Jan 30, 2024. The linked source has what the numbers showed.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":null,"sourceClass":null,"verified":true,"verifiedAt":null},{"id":"354249ccabee7f2a","type":"readout","title":"Phase 3 RAINIER interim met primary and all secondary endpoints in IgAN","drug":"Povetacicept","indication":"IgA nephropathy","phase":"Phase 3","date":"2026-03-09","datePrecision":"day","dateStart":"2026-03-09","dateEnd":"2026-03-09","nctId":null,"outcome":"positive","confidence":"high","summary":"Vertex reported results from its Phase 3 study of Povetacicept for IgA nephropathy on Mar 9, 2026. The study met its main goal.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.biospace.com/press-releases/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"b102d16ba51690f1","type":"other","title":"FDA accepts povetacicept BLA in IgAN; PDUFA target date November 30, 2026","drug":"Povetacicept","indication":"IgA nephropathy","phase":"Phase 3","date":"2026-06-01","datePrecision":"day","dateStart":"2026-06-01","dateEnd":"2026-06-01","nctId":null,"outcome":"positive","confidence":"high","summary":"FDA accepts povetacicept BLA in IgAN; PDUFA target date November 30, 2026, on Jun 1, 2026. A company milestone for Vertex (Povetacicept for IgA nephropathy): a step in the program rather than a decision or a data readout.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.stocktitan.net/news/VRTX/vertex-announces-us-fda-acceptance-of-biologics-license-application-ucojmbxelc7t.html","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"2d9c93668f933249","type":"conference","title":"ALYFTREK Phase 3 data in children ages 2-5 presented at ECFS 2026","drug":"ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)","indication":"Cystic fibrosis","phase":"Phase 3","date":"2026-06-05","datePrecision":"day","dateStart":"2026-06-05","dateEnd":"2026-06-05","nctId":null,"outcome":"positive","confidence":"high","summary":"Vertex presented data on ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for Cystic fibrosis at a medical meeting on Jun 5, 2026. The linked source has the details.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.stocktitan.net/news/VRTX/vertex-presents-new-data-on-alyftrek-at-european-cystic-fibrosis-hb9nbcjolnnk.html","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"82e5b1816c8af56f","type":"conference","title":"CASGEVY pivotal data in children ages 5-11 at EHA, published in NEJM","drug":"CASGEVY (exagamglogene autotemcel)","indication":"Sickle cell disease and transfusion-dependent beta thalassemia","phase":"Pivotal","date":"2026-06-11","datePrecision":"day","dateStart":"2026-06-11","dateEnd":"2026-06-11","nctId":null,"outcome":"positive","confidence":"high","summary":"Vertex presented data on CASGEVY (exagamglogene autotemcel) for Sickle cell disease and transfusion-dependent beta thalassemia at a medical meeting on Jun 11, 2026. The linked source has the details.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.stocktitan.net/news/VRTX/vertex-presents-new-data-on-casgevy-including-first-european-qcpe41zw0t3p.html","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"ba87bbc4d5e973a2","type":"approval","title":"FDA approves expanded CASGEVY use down to age 2 in SCD and beta thalassemia","drug":"CASGEVY (exagamglogene autotemcel)","indication":"Sickle cell disease and transfusion-dependent beta thalassemia, ages 2+","phase":"Pivotal","date":"2026-07-01","datePrecision":"day","dateStart":"2026-07-01","dateEnd":"2026-07-01","nctId":null,"outcome":"approved","confidence":"high","summary":"The FDA approved Vertex’s CASGEVY (exagamglogene autotemcel) for Sickle cell disease and transfusion-dependent beta thalassemia, ages 2+ on Jul 1, 2026. The company can now sell it in that market.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.stocktitan.net/news/VRTX/vertex-announces-us-fda-approval-for-expanded-use-of-casgevy-for-the-tmr3jetswfvy.html","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"c532bbfaee82fc75","type":"other","title":"Vertex acquisition of Crinetics expected to close in Q3 2026","drug":"Paltusotine (PALSONIFY) / atumelnant (Crinetics)","indication":"Acromegaly / endocrine (acquisition)","phase":"Corporate","date":"2026-08-15","datePrecision":"quarter","dateStart":"2026-07-01","dateEnd":"2026-09-30","nctId":null,"outcome":null,"confidence":"high","summary":"Vertex acquisition of Crinetics expected to close in Q3 2026, in Q3 2026 (Jul–Sep). A company milestone for Vertex (Paltusotine (PALSONIFY) / atumelnant (Crinetics) for Acromegaly / endocrine (acquisition)): a step in the program rather than a decision or a data readout.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.biospace.com/press-releases/vertex-reports-second-quarter-2026-financial-results","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"64bb471c0f5208cf","type":"readout","title":"Inaxaplin Phase 2 AMPLIFIED data in AMKD (fall 2026)","drug":"inaxaplin (VX-147)","indication":"APOL1-mediated kidney disease with moderate proteinuria and with Type 2 diabetes","phase":"Phase 2 (AMPLIFIED)","date":"2026-09-30","datePrecision":"half","dateStart":"2026-07-01","dateEnd":"2026-12-31","nctId":null,"outcome":null,"confidence":null,"summary":"Vertex expects to report results from its Phase 2 study of inaxaplin (VX-147) for APOL1-mediated kidney disease with moderate proteinuria and with Type 2 diabetes in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://news.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2026-financial-results","sourceClass":"company_or_other","verified":true,"verifiedAt":null},{"id":"89116aad3f4bcc7e","type":"readout","title":"VX-828 next-generation CF corrector study results","drug":"VX-828","indication":"Cystic fibrosis","phase":"Phase 1/2","date":"2026-09-30","datePrecision":"half","dateStart":"2026-07-01","dateEnd":"2026-12-31","nctId":null,"outcome":null,"confidence":"high","summary":"Vertex expects to report results from its Phase 1/2 study of VX-828 for Cystic fibrosis in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.biospace.com/press-releases/vertex-reports-second-quarter-2026-financial-results","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"90401fa13d0e131d","type":"other","title":"Updated program timelines for zimislecel and VX-017 later in 2026","drug":"Zimislecel (VX-880) / VX-017","indication":"Type 1 diabetes","phase":"Phase 1/2/3","date":"2026-09-30","datePrecision":"half","dateStart":"2026-07-01","dateEnd":"2026-12-31","nctId":null,"outcome":null,"confidence":"high","summary":"Updated program timelines for zimislecel and VX-017 later in 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Vertex (Zimislecel (VX-880) / VX-017 for Type 1 diabetes): a step in the program rather than a decision or a data readout.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://crisprmedicinenews.com/press-release-service/card/vertex-reports-second-quarter-2026-financial-results/","sourceClass":"company_or_other","verified":true,"verifiedAt":null},{"id":"28d22d4cb48b7935","type":"conference","title":"Vertex CF portfolio abstracts at North American Cystic Fibrosis Conference","drug":"ALYFTREK / TRIKAFTA / CF pipeline","indication":"Cystic fibrosis","phase":"Various","date":"2026-10-15","datePrecision":"month","dateStart":"2026-10-01","dateEnd":"2026-10-31","nctId":null,"outcome":null,"confidence":"high","summary":"Vertex presents data on ALYFTREK / TRIKAFTA / CF pipeline for Cystic fibrosis at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://crisprmedicinenews.com/press-release-service/card/vertex-reports-second-quarter-2026-financial-results/","sourceClass":"company_or_other","verified":true,"verifiedAt":null},{"id":"4c0307691cd7f91a","type":"other","title":"Suzetrigine DPN Phase 3 enrollment completion by end of 2026","drug":"Suzetrigine (JOURNAVX)","indication":"Diabetic peripheral neuropathy","phase":"Phase 3","date":"2026-11-15","datePrecision":"quarter","dateStart":"2026-10-01","dateEnd":"2026-12-31","nctId":null,"outcome":null,"confidence":"high","summary":"Suzetrigine DPN Phase 3 enrollment completion by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Vertex (Suzetrigine (JOURNAVX) for Diabetic peripheral neuropathy): a step in the program rather than a decision or a data readout.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://www.biospace.com/press-releases/vertex-reports-second-quarter-2026-financial-results","sourceClass":"secondary","verified":true,"verifiedAt":null},{"id":"5a0e098daefc242c","type":"readout","title":"Inaxaplin Phase 3 AMPLITUDE interim analysis in AMKD","drug":"inaxaplin (VX-147)","indication":"APOL1-mediated kidney disease","phase":"Phase 2/3 (AMPLITUDE, pre-specified interim analysis)","date":"2026-11-15","datePrecision":"quarter","dateStart":"2026-10-01","dateEnd":"2026-12-31","nctId":null,"outcome":null,"confidence":null,"summary":"Vertex expects to report results from its Phase 2/3 study of inaxaplin (VX-147) for APOL1-mediated kidney disease in Q4 2026 (Oct–Dec) (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://news.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2026-financial-results","sourceClass":"company_or_other","verified":true,"verifiedAt":null},{"id":"4b983368e811d09b","type":"pdufa","title":"PDUFA date for povetacicept accelerated approval in IgA nephropathy","drug":"povetacicept (dual BAFF/APRIL inhibitor)","indication":"IgA nephropathy (accelerated approval)","phase":"BLA under FDA review (Phase 3 RAINIER interim)","date":"2026-11-30","datePrecision":"day","dateStart":"2026-11-30","dateEnd":"2026-11-30","nctId":null,"outcome":null,"confidence":null,"summary":"The FDA is due to decide by Nov 30, 2026 whether to approve Vertex’s povetacicept (dual BAFF/APRIL inhibitor) for IgA nephropathy (accelerated approval). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-biologics-license-application","sourceClass":"company_or_other","verified":true,"verifiedAt":null},{"id":"81b86103a39a058e","type":"readout","title":"Inaxaplin AMPLITUDE Phase 2/3 interim analysis data in early 2027","drug":"Inaxaplin (VX-147)","indication":"APOL1-mediated kidney disease","phase":"Phase 2/3","date":"2027-03-30","datePrecision":"half","dateStart":"2027-01-01","dateEnd":"2027-06-30","nctId":null,"outcome":null,"confidence":"high","summary":"Vertex expects to report results from its Phase 2/3 study of Inaxaplin (VX-147) for APOL1-mediated kidney disease in the first half of 2027 (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.","summaryBy":"template","summaryAt":null,"source":"curated","sourceUrl":"https://crisprmedicinenews.com/press-release-service/card/vertex-reports-second-quarter-2026-financial-results/","sourceClass":"company_or_other","verified":true,"verifiedAt":null}],"catalystsTotal":16,"catalystsTruncated":false,"catalystsPage":{"limit":100,"offset":0,"total":16,"nextOffset":null},"clinicalTrials":{"records":null,"reason":"not_redistributed","snapshot":{"status":"not_synced","fetchedAt":null,"ok":null,"storedStudyCount":null},"linkedNctIds":[]}}],"freshness":{"responseGeneratedAt":"2026-10-29T20:48:23.495Z","sourceProcessedAt":null,"jobsEnabled":false,"hostedResearchSchedule":"off","database":"sqlite","tickerMapFetchedAt":null,"fdaCalendarFetchedAt":null},"coverage":{"categories":["ai-drug-discovery","antisense","cardiology","cell-therapy","gene-editing","gene-therapy","immunology","large-biotech","large-pharma","liver","mrna","neuro","obesity","oncology","platform","protein-degradation","pulmonology","rare-disease","rnai","vaccines","virology"],"rateLimit":{"perMinute":120,"burst":40,"scope":"single_process_memory"},"cache":{"success":"public, s-maxage=300, stale-while-revalidate=900","errors":"no-store"},"secTickerMap":{"fetchedAt":null,"ok":null},"fdaAdvisoryCalendar":{"redistributed":false,"fetchedAt":null,"ok":null}},"fdaAdvisoryMeetings":null,"nulls":{"sec.cik":"No CIK is stored for this company. The preview does not look one up during the request.","sec.conformedName":"Absent unless company_tickers.json has been synced into this database.","sec.filingsUrl":"Absent when cik is absent. The URL is an EDGAR search link, not a filing.","catalyst.confidence":"Null when the curated seed left confidence unset. The database loader stores high in that case; this API does not repeat that default.","catalyst.summary":"Null when no eligible admin or research note is stored and the field template cannot be built. The template is our two-sentence explanation of the published catalog fields. It is not a source body. A stored note over 400 characters, or one that contains a URL, is not eligible.","catalyst.summaryAt":"Null when summary is null, when summaryBy is template, when the sentence matches the seed file, or when no separate write time is stored. A template has no timestamp: response generation is not a source or editorial date. The seed loader stamps summary_at at startup, and the seed file has no authorship time, so that clock is not published. A research note or a later edit whose text is not the seed sentence keeps its stored time.","catalyst.summaryBy":"Null when summary is null. Otherwise admin, research, or template. template means this response generated the sentence from published fields.","catalyst.verifiedAt":"Null when no verification pass recorded a time. verified true on a curated row means the row was accepted into the seed, not that someone re-checked it on a known date.","catalyst.sourceUrl":"Null when the row has no http(s) link, or the only link is a Google News wrapper.","catalyst.sourceClass":"Null when sourceUrl is null. company_or_other is not a finding that the host is the company’s official site.","catalyst.nctId":"Null when the curated row does not name a ClinicalTrials.gov study.","catalyst.outcome":"Null when the row has no short outcome label, or the stored text is not one of the known labels.","catalyst.drug":"Null when the curated row does not name a drug.","catalyst.indication":"Null when the curated row does not name an indication.","catalyst.phase":"Null when the curated row does not name a phase.","catalyst.dateStart":"Null only when the row has no window start.","catalyst.dateEnd":"Null only when the row has no window end.","clinicalTrials.records":"Always null. Study records are not redistributed in this preview.","clinicalTrials.snapshot.fetchedAt":"Null when this database has no trials sync row for the company.","clinicalTrials.snapshot.storedStudyCount":"Null when studies were never synced here. A number is a row count, not a claim that the set is current.","clinicalTrials.linkedNctIds":"NCT ids on the catalysts in this page only. An empty array means this page has none. Other pages are not included.","fdaAdvisoryMeetings":"Always null. Advisory meetings are not matched to a company, and their titles are not copied.","freshness.sourceProcessedAt":"Always null. The seed has no single source-processing timestamp, and this response does not invent one."},"notices":["Public developer preview. No API key, no account, no paid plan, and no uptime or freshness guarantee.","The Vercel deployment serves the reviewed seed from disposable SQLite. It does not run the research schedule. Its cron checks the activity cache only.","jobsEnabled describes this process. True means a long-lived server may start jobs. It does not mean a research run succeeded or that sources are current.","ClinicalTrials.gov study text is not included. Posted terms expect current data and the date ClinicalTrials.gov processed it. This preview keeps neither.","FDA advisory-meeting titles are not included. The calendar feed does not name a sponsor in a way this app trusts.","SEC CIK is included only when this database already stores one, on the ticker map or the company row. The EDGAR conformed name comes only from the ticker map. Filing documents are not included.","summary is a stored admin or research note when one is eligible: at most 400 characters and no URL. Otherwise it is a template sentence from the published title, drug, indication, phase, date, precision, outcome, ticker, and company name. The template limit is 1600 characters and a longer sentence is omitted whole, not cut. summaryAt is null for a template. It is also null when a stored sentence matches the seed, because the loader clock is startup, not authorship. A missing confidence is null, not high.","sourceUrl points at a page. It is not permission to copy that page. Wire and secondary hosts are labeled.","Omitted on purpose: prices, market cap, returns, index weights, price reactions, congressional and other trade records, news headlines, and press-release or article bodies.","The rate limit is an in-memory bucket on one server process. Serverless isolates do not share it, so it is not a global quota."]}